Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
208 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016', provides an overview of the H5N1 Infection (Avian Influenza) pipeline landscape. The report provides comprehensive information on the therapeutics under development for H5N1 Infection (Avian Influenza), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H5N1 Infection (Avian Influenza) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews pipeline therapeutics for H5N1 Infection (Avian Influenza) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved H5N1 Infection (Avian Influenza) therapeutics and enlists all their major and minor projects - The report assesses H5N1 Infection (Avian Influenza) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for H5N1 Infection (Avian Influenza) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 H5N1 Infection (Avian Influenza) Overview 7 Therapeutics Development 8 H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies 10 H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes 13 H5N1 Infection (Avian Influenza) - Pipeline Products Glance 14 H5N1 Infection (Avian Influenza) - Products under Development by Companies 17 H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes 21 H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development 22 H5N1 Infection (Avian Influenza) - Therapeutics Assessment 60 Drug Profiles 70 H5N1 Infection (Avian Influenza) - Recent Pipeline Updates 158 H5N1 Infection (Avian Influenza) - Dormant Projects 186 H5N1 Infection (Avian Influenza) - Discontinued Products 191 H5N1 Infection (Avian Influenza) - Product Development Milestones 192 Appendix 199
List of Tables
Number of Products under Development for H5N1 Infection (Avian Influenza), H1 2016 16 Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H1 2016 17 Number of Products under Development by Companies, H1 2016 18 Number of Products under Development by Companies, H1 2016 (Contd..1) 19 Number of Products under Development by Companies, H1 2016 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H1 2016 21 Comparative Analysis by Late Stage Development, H1 2016 22 Comparative Analysis by Clinical Stage Development, H1 2016 23 Comparative Analysis by Early Stage Development, H1 2016 24 Products under Development by Companies, H1 2016 25 Products under Development by Companies, H1 2016 (Contd..1) 26 Products under Development by Companies, H1 2016 (Contd..2) 27 Products under Development by Companies, H1 2016 (Contd..3) 28 Products under Investigation by Universities/Institutes, H1 2016 29 H5N1 Infection (Avian Influenza) - Pipeline by Akshaya Bio Inc., H1 2016 30 H5N1 Infection (Avian Influenza) - Pipeline by Altimmune, Inc., H1 2016 31 H5N1 Infection (Avian Influenza) - Pipeline by Antigen Express, Inc., H1 2016 32 H5N1 Infection (Avian Influenza) - Pipeline by Aphios Corporation, H1 2016 33 H5N1 Infection (Avian Influenza) - Pipeline by BioDiem Ltd, H1 2016 34 H5N1 Infection (Avian Influenza) - Pipeline by BiondVax Pharmaceuticals Ltd., H1 2016 35 H5N1 Infection (Avian Influenza) - Pipeline by CEL-SCI Corporation, H1 2016 36 H5N1 Infection (Avian Influenza) - Pipeline by Cocrystal Pharma, Inc., H1 2016 37 H5N1 Infection (Avian Influenza) - Pipeline by CSL Limited, H1 2016 38 H5N1 Infection (Avian Influenza) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 39 H5N1 Infection (Avian Influenza) - Pipeline by Emergent BioSolutions Inc., H1 2016 40 H5N1 Infection (Avian Influenza) - Pipeline by Gemmus Pharma Inc., H1 2016 41 H5N1 Infection (Avian Influenza) - Pipeline by GlaxoSmithKline Plc, H1 2016 42 H5N1 Infection (Avian Influenza) - Pipeline by Hemispherx Biopharma, Inc., H1 2016 43 H5N1 Infection (Avian Influenza) - Pipeline by iBio, Inc., H1 2016 44 H5N1 Infection (Avian Influenza) - Pipeline by Immunovaccine, Inc., H1 2016 45 H5N1 Infection (Avian Influenza) - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 46 H5N1 Infection (Avian Influenza) - Pipeline by Johnson & Johnson, H1 2016 47 H5N1 Infection (Avian Influenza) - Pipeline by Kineta, Inc., H1 2016 48 H5N1 Infection (Avian Influenza) - Pipeline by Medicago Inc., H1 2016 49 H5N1 Infection (Avian Influenza) - Pipeline by MedImmune, LLC, H1 2016 50 H5N1 Infection (Avian Influenza) - Pipeline by Microbiotix, Inc., H1 2016 51 H5N1 Infection (Avian Influenza) - Pipeline by NanoBio Corporation, H1 2016 52 H5N1 Infection (Avian Influenza) - Pipeline by Nanotherapeutics, Inc., H1 2016 53 H5N1 Infection (Avian Influenza) - Pipeline by NanoViricides, Inc., H1 2016 54 H5N1 Infection (Avian Influenza) - Pipeline by NewLink Genetics Corporation, H1 2016 55 H5N1 Infection (Avian Influenza) - Pipeline by OPKO Health, Inc., H1 2016 56 H5N1 Infection (Avian Influenza) - Pipeline by PaxVax, Inc., H1 2016 57 H5N1 Infection (Avian Influenza) - Pipeline by PeptiDream Inc., H1 2016 58 H5N1 Infection (Avian Influenza) - Pipeline by Protein Sciences Corporation, H1 2016 59 H5N1 Infection (Avian Influenza) - Pipeline by Shionogi & Co., Ltd., H1 2016 60 H5N1 Infection (Avian Influenza) - Pipeline by Sirnaomics, Inc., H1 2016 61 H5N1 Infection (Avian Influenza) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 62 H5N1 Infection (Avian Influenza) - Pipeline by TechnoVax, Inc., H1 2016 63 H5N1 Infection (Avian Influenza) - Pipeline by TGV-Laboratories, H1 2016 64 H5N1 Infection (Avian Influenza) - Pipeline by Theraclone Sciences, Inc., H1 2016 65 H5N1 Infection (Avian Influenza) - Pipeline by Vaxine Pty Ltd, H1 2016 66 H5N1 Infection (Avian Influenza) - Pipeline by VaxInnate Corporation, H1 2016 67 Assessment by Monotherapy Products, H1 2016 68 Assessment by Combination Products, H1 2016 69 Number of Products by Stage and Target, H1 2016 71 Number of Products by Stage and Mechanism of Action, H1 2016 73 Number of Products by Stage and Route of Administration, H1 2016 75 Number of Products by Stage and Molecule Type, H1 2016 77 H5N1 Infection (Avian Influenza) Therapeutics - Recent Pipeline Updates, H1 2016 166 H5N1 Infection (Avian Influenza) - Dormant Projects, H1 2016 194 H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..1), H1 2016 195 H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..2), H1 2016 196 H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..3), H1 2016 197 H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..4), H1 2016 198 H5N1 Infection (Avian Influenza) - Discontinued Products, H1 2016 199
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
